Related references
Note: Only part of the references are listed.Emerging Therapeutic Options in Age-Related Macular Degeneration
Giuseppe Querques et al.
OPHTHALMIC RESEARCH (2015)
Seeing through VEGF: innate and adaptive immunity in pathological angiogenesis in the eye
Abdoulaye Sene et al.
TRENDS IN MOLECULAR MEDICINE (2015)
Intravitreal administration of bevacizumab: pros and cons
Simin Dashti-Khavidaki et al.
DARU-JOURNAL OF PHARMACEUTICAL SCIENCES (2015)
A single-arm, investigator-initiated study of the efficacy, safety and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration, previously treated with ranibizumab or bevacizumab: 6-month interim analysis
Rishi P. Singh et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2014)
Long-term results of intravitreal ranibizumab for the treatment of retinal angiomatous proliferation and utility of an advanced RPE analysis performed using spectral-domain optical coherence tomography
Maiko Inoue et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2014)
Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD
Robert L. Avery et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2014)
Aflibercept treatment for patients with exudative age-related macular degeneration who were incomplete responders to multiple ranibizumab injections (TURF trial)
Charles C. Wykoff et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2014)
Retinal and choroidal thickness changes after single anti-VEGF injection in neovascular age-related macular degeneration: ranibizumab vs bevacizumab
Selcuk Sizmaz et al.
EUROPEAN JOURNAL OF OPHTHALMOLOGY (2014)
Initial utilization of aflibercept in exudative age-related macular degeneration
Hyung Cho et al.
EUROPEAN JOURNAL OF OPHTHALMOLOGY (2014)
Bevacizumab for choroidal neovascularization secondary to age-related macular degeneration and pathological myopia
Saba Hashemi et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2014)
Twenty-four-Month Efficacy and Safety of 0.5 mg or 2.0 mg Ranibizumab in Patients with Subfoveal Neovascular Age-Related Macular Degeneration
Allen C. Ho et al.
OPHTHALMOLOGY (2014)
Intravitreal Aflibercept Injection for Neovascular Age-related Macular Degeneration Ninety-Six-Week Results of the VIEW Studies
Ursula Schmidt-Erfurth et al.
OPHTHALMOLOGY (2014)
Age-Related Macular Degeneration: Linking Clinical Presentation to Pathology
Lisa Nivison-Smith et al.
OPTOMETRY AND VISION SCIENCE (2014)
INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR FOR RETINAL ANGIOMATOUS PROLIFERATION IN TREATMENT-NAIVE EYES Long-term Functional and Anatomical Results Using A Modified PrONTO-Style Regimen
Magda Gharbiya et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2014)
Aflibercept Therapy for Exudative Age-related Macular Degeneration Resistant to Bevacizumab and Ranibizumab
Benjamin Bakall et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2013)
Aflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumab
Hyung Cho et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2013)
Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature
K. Ghasemi Falavarjani et al.
EYE (2013)
Cellular and molecular mechanisms of age-related macular degeneration: From impaired autophagy to neovascularization
Alexa Klettner et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2013)
Lutein plus Zeaxanthin and Omega-3 Fatty Acids for Age-Related Macular Degeneration The Age-Related Eye Disease Study 2 (AREDS2) Randomized Clinical Trial
Emily Y. Chew et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)
Therapy of stage III retinal angiomatous proliferation. Intravitreal ranibizumab injections
M. Maier et al.
OPHTHALMOLOGE (2013)
Combination Therapy for Neovascular Age-related Macular Degeneration Refractory to Anti-Vascular Endothelial Growth Factor Agents
Kevin Tozer et al.
OPHTHALMOLOGY (2013)
Super-dose Anti-VEGF (SAVE) Trial: 2.0 mg Intravitreal Ranibizumab for Recalcitrant Neovascular Macular Degeneration-Primary End Point
David M. Brown et al.
OPHTHALMOLOGY (2013)
Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial
Laurent Kodjikian et al.
OPHTHALMOLOGY (2013)
VISUAL AND ANATOMICAL OUTCOMES OF INTRAVITREAL AFLIBERCEPT IN EYES WITH PERSISTENT SUBFOVEAL FLUID DESPITE PREVIOUS TREATMENTS WITH RANIBIZUMAB IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Nishant Kumar et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2013)
Aflibercept in wet AMD: specific role and optimal use
F. Semeraro et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2013)
Intravitreal ranibizumab treatment of retinal angiomatous proliferation
Christina A. Kramann et al.
ACTA OPHTHALMOLOGICA (2012)
Aflibercept (VEGF Trap-eye): the newest anti-VEGF drug
Michael W. Stewart
BRITISH JOURNAL OF OPHTHALMOLOGY (2012)
Comparison of outcomes after switching treatment from intravitreal bevacizumab to ranibizumab in neovascular age-related macular degeneration
Jerrod S. Kent et al.
CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE (2012)
Verteporfin plus Ranibizumab for Choroidal Neovascularization in Age-related Macular Degeneration Twelve-month MONT BLANC Study Results
Michael Larsen et al.
OPHTHALMOLOGY (2012)
Ranibizumab and Bevacizumab for Treatment of Neovascular Age-Related Macular Degeneration
Daniel F. Martin et al.
OPHTHALMOLOGY (2012)
Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular Degeneration
Jeffrey S. Heier et al.
OPHTHALMOLOGY (2012)
Ranibizumab versus Bevacizumab to Treat Neovascular Age-related Macular Degeneration
Usha Chakravarthy et al.
OPHTHALMOLOGY (2012)
The DA VINCI Study: Phase 2 Primary Results of VEGF Trap-Eye in Patients with Diabetic Macular Edema
Diana V. Do et al.
OPHTHALMOLOGY (2011)
Bevacizumab and Neovascular Age Related Macular Degeneration: Pathogenesis and Treatment
Georges M. El-Mollayess et al.
SEMINARS IN OPHTHALMOLOGY (2011)
Phakic intraocular lenses
Rajesh Sinha et al.
INDIAN JOURNAL OF OPHTHALMOLOGY (2009)
Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 1
Carl D. Regillo et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2008)
Neovascular age-related macular degeneration - Potential therapies
Aimee V. Chappelow et al.
DRUGS (2008)
Types of choroidal neovascularisation in newly diagnosed exudative age-related macular degeneration
S. Y. Cohen et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2007)
Ranibizumab for neovascular age-related macular degeneration
Philip J. Rosenfeld et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Ranibizumab versus verteporfin for neovascular age-related macular degeneration
David M. Brown et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease
EWM Ng et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Treatment of retinal angiomatous proliferation in age-related macular degeneration - A series of 104 cases of retinal angiomatous proliferation
F Bottoni et al.
ARCHIVES OF OPHTHALMOLOGY (2005)
Pegaptanib for neovascular age-related macular degeneration
ES Gragoudas et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Share Paper
